Characteristics of Patients With Universal Vitiligo and Health-Related Quality of Life

Homan, May W. Linthorst; Sprangers, Mirjam A. G.; Korte, J. de; Bos, Jan D.; Veen, J.P.W. van der

doi:10.1001/archderm.144.8.1062

Cited by 16 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Skindex total score can be interpreted as having very little effect (score ≤ 5), mild effect (scores 6–17), moderate effect (scores 18–36) and severe effect (scores ≥ 37) on QoL 118 . The Skindex‐29 was administered in 15 studies 33,39,118–130 . Among studies that reported mean global scores in the overall population, scores ranged from 20.8 to 33.1 39,121–123,125 ; these scores indicate that vitiligo had moderate effects on patients’ lives (Fig.…”

Section: Resultsmentioning

confidence: 99%

“… 118 The Skindex‐29 was administered in 15 studies. 33 , 39 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 Among studies that reported mean global scores in the overall population, scores ranged from 20.8 to 33.1 39 , 121 , 122 , 123 , 125 ; these scores indicate that vitiligo had moderate effects on patients’ lives (Fig. 2b ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

Picardo

Huggins

Jones

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Despite historical mischaracterization as a cosmetic condition, patients with the autoimmune disorder vitiligo experience substantial quality-of-life (QoL) burden. This systematic literature review of peer-reviewed observational and interventional studies describes comprehensive evidence for humanistic burden in patients with vitiligo. PubMed, EMBASE, Scopus and the Cochrane databases were searched through February 10, 2021, to qualitatively assess QoL in vitiligo. Two independent reviewers assessed articles for inclusion and extracted data for qualitative synthesis. A total of 130 included studies were published between 1996 and 2021. Geographical regions with the most studies were Europe (32.3%) and the Middle East (26.9%). Dermatology-specific instruments, including the Dermatology Life Quality Index (DLQI; 80 studies) and its variants for children (CDLQI; 10 studies) and families (FDLQI; 4 studies), as well as Skindex instruments (Skindex-29, 15 studies; Skindex-16, 4 studies), were most commonly used to measure humanistic burden. Vitiligospecific instruments, including the Vitiligo-specific QoL (VitiQoL; 11 studies) instrument and 22-item Vitiligo Impact Scale (VIS-22; 4 studies), were administered in fewer studies. Among studies that reported total scores for the overall population, a majority revealed moderate or worse effects of vitiligo on patient QoL (DLQI, 35/54 studies; Skindex, 8/8 studies; VitiQoL, 6/6 studies; VIS-22, 3/3 studies). Vitiligo also had a significant impact on the QoL of families and caregivers; 4/4 studies reporting FDLQI scores indicated moderate or worse effects on QoL. In general, treatment significantly (P < 0.05) improved QoL, but there were no trends for types or duration of treatment. Among studies that reported factors significantly (P ≤ 0.05) associated with reduced QoL, female sex and visible lesions and/or lesions in sensitive areas were most common. In summary, vitiligo has clinically meaningful effects on the QoL of patients, highlighting that greater attention should be dedicated to QoL decrement awareness and improvement in patients with vitiligo.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

Picardo

Huggins

Jones

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…In more than 50% of cases, the disease onset is prior to the age of 20 years 3 and is progressive especially in the first 10–20 years 4 . Although the disease usually does not cause any objective physical complaints, it is associated in the majority of patients with marked limitations of health‐related quality of life (QoL) 5,6 . This results apparently from a perceived stigmatization 7 especially in cases where the disease affects visible parts of the body or the genitals.…”

mentioning

confidence: 99%

Willingness-to-pay and quality of life in patients with vitiligo

Radtke¹,

Schäfer²,

Gajur³

et al. 2009

British Journal of Dermatology

146

148

View full text Add to dashboard Cite

show abstract

“…Patients with vitiligo develop white patches on their skin, including in visible areas such as the face, neck, hands, and forearms. As a result, the quality of life of vitiligo patients can be severely reduced (2)(3)(4)(5). Clinically two major types of vitiligo are recognized: segmental vitiligo (SV), which affects a localized asymmetrical area of the body, and nonsegmental vitiligo (NSV), the more common subtype, which often involves multiple body sites in a symmetrical fashion.…”

Section: Introductionmentioning

confidence: 99%

Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response

Yang

Zhang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Vitiligo is an acquired depigmentation skin disease caused by immune-mediated death of melanocytes. The most common treatment for vitiligo is narrow band ultraviolet B phototherapy, which often is combined with topical therapies such as tacrolimus. However, patients’ responses to these treatments show large variations. To date, the mechanism for this heterogeneity is unknown, and there are no molecular indicators that can predict an individual patient’s response to therapy. The goal of this study is to identify clinical parameters and gene expression biomarkers associated with vitiligo response to therapy. Six patients with segmental vitiligo and 30 patients with non-segmental vitiligo underwent transcriptome sequencing of lesional and nonlesional skin at baseline before receiving combined UBUVB and tacrolimus therapy for 6 month, and were separated into good response and bad response groups based on target lesion achieving > 10% repigmentation or not. Our study revealed that treatment-responsive vitiligo lesions had significantly shorter disease duration compared with non-responsive vitiligo lesions (2.5 years vs 11.5 years, p=0.046, t-Test), while showing no significant differences in the age, gender, ethnicity, vitiligo subtype, or disease severity. Transcriptomic analyses identified a panel of 68 genes separating the good response from bad response lesions including upregulation of immune active genes, such as CXCL10, FCRL3, and TCR, Further, compared with vitiligo lesions with long disease duration, the lesions with short duration also have much higher level of expression of immune-active genes, including some (such as FCRL3 and TCR genes) that are associated with favorable therapeutic response. In conclusion, our study has identified clinical parameters such as short disease duration and a panel of immune active and other gene expression biomarkers that are associated with favorable response to immune suppressive NBUVB + tacrolimus therapy. These markers may be useful clinically for individualized therapeutic management of vitiligo patients in the future.

show abstract

Characteristics of Patients With Universal Vitiligo and Health-Related Quality of Life

Cited by 16 publications

References 4 publications

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes

Willingness-to-pay and quality of life in patients with vitiligo

Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response

Contact Info

Product

Resources

About